* In most patients with SM-CEL and rearranged PDGFR, no KIT mutation is found; therefore, neoplastic cells are usually responsive to imatinib in these patients.

† In most patients with ASM, neoplastic cells exhibit KIT D816V or another KIT mutation conferring resistance against imatinib; therefore, only PKC412 is considered to elicit major and durable responses in these patients.

‡ A special subvariant is ASM-t, in which transformation to MCL is visible.